What this is
- How it works
- How it works isn't classified yet
- Tested for
- HIV-1-infection
- Main trialPhase 1
- “Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).”In the company’s words, NCT05143307 on ClinicalTrials.gov
Other drugs for HIV-1-infection
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- IslatravirMerck & Co. · Phase 2/3
- UlonivirineMerck & Co. · Phase 2/3
- ISL/ULOMerck & Co. · Phase 2/3
- CabotegravirViiV Healthcare · Phase 3
Coming up1
- Jan 2037Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Enrolling by invitation | Jan 2037 | Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101 | |
| Phase 1Completed | 14 Nov 2024 | Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026